|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bourcier K, Le Cense A, Tselikas L, Adam
J, Mir L, Honore C and de Baere T: Basic knowledge in soft tissue
sarcoma. Cardiovasc Intervent Radiol. 42:1255–1261. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pisters PW, Leung DH, Woodruff J, Shi W
and Brennan MF: Analysis of prognostic factors in 1,041 patients
with localized soft tissue sarcomas of the extremities. J Clin
Oncol. 14:1679–1689. 1996.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Callegaro D, Miceli R, Bonvalot S,
Ferguson P, Strauss DC, Levy A, Griffin A, Hayes AJ, Stacchiotti S,
Pechoux CL, et al: Development and external validation of two
nomograms to predict overall survival and occurrence of distant
metastases in adults after surgical resection of localised
soft-tissue sarcomas of the extremities: A retrospective analysis.
Lancet Oncol. 17:671–680. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
De Sanctis R, Zelic R and Santoro A:
Nomograms predicting local and distant recurrence and
diease-specific mortality for R0/R1 soft tissue sarcomas of the
extremities. Front Oncol. 12(941896)2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gronchi A, Miah AB, Dei Tos AP, Abecassis
N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, et
al: ESMO guidelines committee, EURACAN and GENTURIS. Soft tissue
and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice
guidelines for diagnosis, treatment, and follow-up. Ann Oncol.
32:1348–1365. 2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Tanaka K, Mizusawa J, Naka N, Kawai A,
Katagiri H, Hiruma T, Matsumoto Y, Tsuchiya H, Nakayama R, Hatano
H, et al: Ten-year follow-up results of perioperative chemotherapy
with doxorubicin and ifosfamide for high-grade soft tissue sarcoma
of the extremities: Japan clinical oncology group study of
JCOG0304. BMC Cancer. 19(890)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Nakamura T, Asanuma K, Takao M, Yamanaka
T, Koike H, Chen-Yoshikawa TF, Tsukushi S, Kuroda H, Kozawa E, Sano
M, et al: Clinical outcome in soft tissue sarcoma patients with
lung metastasis who received metastasectomy and/or radiofrequency
ablation: Tokai Musculoskeletal oncology consortium study. Cancer
Manag Res. 13:8473–8480. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kawamoto T, Hara H, Morishita M, Fukase N,
Kawakami Y, Takemori T, Fujiwara S, Kitayama K, Yahiro S, Miyamoto
T, et al: Prognostic influence of the treatment approach for
pulmonary metastasis in patients with soft tissue sarcoma. Clin Exp
Metastasis. 37:509–517. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Smrke A, Wang Y and Simmons C: Update on
systemic therapy for advanced soft-tissue sarcoma. Curr Oncol.
27:25–33. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to Virchow? Lancet. 357:539–545. 2001.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Colotta JF, Allavena P, Sica A, Garlanda C
and Mantovani A: Cancer-related inflammation, the seventh hallmark
of cancer: Links to genetic instability. Carcinogenesis.
30:1073–1081. 2009.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hart PC, Rajab IM, Alebraheem M and
Potempa LA: C-reactive protein and cancer-diagnostic and
therapeutic insights. Front Immunol. 11(595835)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wu ES, Oduyebo T, Cobb LP, Cholakian D,
Kong X, Fader AN, Levinson KL, Tanner EJ III, Stone RL, Piotrowski
A, et al: Lymphopenia and its association with survival in patients
with locally advanced cervical cancer. Gynecol Oncol. 140:76–82.
2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Matsuyama Y, Nakamura T, Yoshida K,
Nakamura K, Hagi T, Asanuma K and Sudo A: Role the prognostic
nutritional index in patients with soft tissue sarcoma. In Vivo.
35:2349–2355. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kitamura H, Ohno Y, Toyoshima Y, Ohtake J,
Homma S, Kawamura H, Takahashi N and Taketomi A:
Interleukin-6/STAT3 signaling as a promising target to improve the
efficacy of cancer immunotherapy. Cancer Sci. 108:1947–1952.
2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Castell JV, Gómez-Lechón MJ, David M,
Fabra R, Trullenque R and Heinrich PC: Acute-phase response of
human hepatocytes; regulation of acute-phase protein synthesis by
interleukin-6. Hepatology. 12:1179–1186. 1990.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Nakamura K, Nakamura T, Iino T, Hagi T,
Kita K, Asanuma K and Sudo A: Expression of interleukin-6 and the
interleukin-6 receptor predicts the clinical outcome of patients
with soft tissue sarcomas. Cancers (Basel). 12(585)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Fu Q, Chang Y, An H, Fu H, Zhu Y, Xu L,
Zhang W and Xu J: Prognostic value of interleukin-6 and
interleukin-6 receptor in organ-confined clear-cell renal cell
carcinoma: A 5-year conditional cancer-specific survival analysis.
Br J Cancer. 113:1581–1589. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hagi T, Nakamura T, Iino T, Matsubara T,
Asanuma K, Matsumine A and Sudo A: The diagnostic and prognostic
value of interleukin-6 in patients with soft tissue sarcomas. Sci
Rep. 7(9640)2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Rutkowski P, Kaminska J, Kowalska M, Ruka
W and Steffen J: Cytokine serum levels in soft tissue sarcoma
patients: Correlations with clinic-pathological features and
prognosis. Int J Cancer. 100:463–471. 2002.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Can C, Acikalin MF, Ozen A and Dundar E:
Prognostic impact of intratumoral C-reactive protein expression in
patients with clear cell renal cell carcinoma. Urol Int.
92:270–275. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Nazoe T, Korenaga D, Futatsugi M, Saeki H,
Maehara Y and Sugimachi K: Immunohistochemical expression of
C-reactive protein in squamous cell carcinoma of the
esophagus-significance as a tumor maker. Cancer Lett. 192:89–95.
2003.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Bruno F, Arrigoni F, Mariani S, Splendiani
A, Cesare ED, Masciocchi C and Barile A: Advanced magnetic
resonance imaging (MRI) of soft tissue tumors: Techniques and
applications. Radiol Med. 124:243–252. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Costa FM, Martins PH, Canella C and Lopes
FPPL: Mutliparametric MR imaging of soft tissue tumors and
psudotumors. Magn Reson Imaging Clin N Am. 26:543–558.
2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Beaman FD, Jelinek JS and Priebat DA:
Current imaging and therapy of malignant soft tissue tumors and
tumor-like lesions. Semin Musculoskelet Radiol. 17:168–176.
2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Nakamura T, Matsumine A, Iino T, Matsubara
T, Asanuma K, Uchida A and Sudo A: Role of high- sensitivity
C-reactive protein in the differentiation of benign and malignant
soft tissue tumors. Anticancer Res. 34:933–936. 2014.PubMed/NCBI
|
|
29
|
Ariizumi T, Kawashima H, Ogose A, Sasaki
T, Hotta T, Hatano H, Morita T and Endo N: The diagnostic and
prognostic value of hematological and chemical abnormalities in
soft tissue sarcomas: A comparative study in patients with benign
and malignant soft tissue tumors. Ann Clin Lab Sci. 48:11–17.
2018.PubMed/NCBI
|
|
30
|
Fujibuchi T, Miyawaki J, Kidani T, Imai H
and Miura H: Prediction of soft tissue sarcoma from clinical
characteristics and laboratory data. Cancers (Basel).
12(679)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yano Y, Ohno T, Komura K, Fukuokaya W,
Uchimoto T, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A,
Yamazaki S, et al: Serum C-reactive protein level predicts overall
survival for clear cell and non clear cell renal cell carcinoma
treated with lpilimumab plus nivolmab. Cancers (Basel).
14(5659)2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Patel SH, Derweesh IH, Saito K, Patil D,
Meagher MF, Bindayi A, Eldefrawy A, Patel DN, Nasseri R, Yasuda Y,
et al: Preoperative elevation of C-reactive protein is a predictor
for adverse oncologic survival outcomes for renal cell carcinoma:
Analysis from the international market consortium renal cancer
(INMARC). Clin Genitourin Cancer. 19:e206–e215. 2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ghuman S, Van Hemelrijck M, Garmo H,
Holmberg L, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I
and Wulaningsih W: Serum inflammatory markers and colorectal cancer
risk and survival. Br J Cancer. 116:1358–1365. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Okada S, Shimomura M, Tsunezuka H,
Teramukai S, Ishihara S, Shimada J and Inoue M: Prognostic
significance of preoperative C-reactive protein in resected
non-small cell lung cancer. Semin Thorac Cardiovasc Surg.
32:1046–1055. 2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Lu J, Xu BB, Xue Z, Xie JW, Zheng CH,
Huang CM and Li P: Prioperative CRP: A novel inflammation-based
classification in gastric cancer for recurrence and chemotherapy
benefit. Cancer Med. 10:34–44. 2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Liao DW, Hu X, Wang Y, Yang ZQ and Li X:
C-reactive protein is a predictor of prognosis of prostate cancer:
A systematic review and meta-analysis. Ann Clin Lab Sci.
50:161–171. 2020.PubMed/NCBI
|
|
37
|
Ishibashi Y, Tsujimoto H, Hiraki S, Kumano
I, Yaguchi Y, Horiguchi H, Nomura S, Ito N, Shinto E, Aosasa S, et
al: Prognostic value of preoperative systemic inflammatory measures
in patients with esophageal cancer. Ann Surg Oncol. 25:3288–3299.
2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Nakamura T, Matsumine A, Matsubara T,
Asanuma K, Uchida A and Sudo A: Clinical significance of
pretreatment C-reactive protein level in soft tissue sarcoma.
Cancer. 118:1055–1061. 2012.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Guillou L, Coindre JM, Bonichon F, Nguyen
BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le Doussal V,
Leroux A, et al: Comparative study of the national cancer institute
and french federation of cancer centers sarcoma group grading
systems in a population of 410 adult patients with soft tissue
sarcoma. J Clin Oncol. 15:350–362. 1997.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Nakamura T, Grimer R, Gaston C, Francis M,
Charman J, Graunt P, Uchida A, Sudo A and Jeys L: The value of
C-reactive protein and comorbidity in predicting survival of
patients with high grade soft tissue sarcoma. Eur J Cancer.
49:377–385. 2013.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Szkandera J, Gerger A, Liegl-Atzwanger B,
Absenger G, Stotz M, Samonigg H, Maurer-Ertl W, Stojakovic T,
Ploner F, Leithner A and Pichler M: Validation of the prognostic
relevance of C-reactive protein levels in soft tissue sarcoma
patients. Br J Cancer. 109:2316–2322. 2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Choi ES, Kim HS and Han I: Elevated
preoperative systemic inflammatory markers predict poor outcome in
localized soft tissue sarcoma. Ann Surg Oncol. 21:778–785.
2014.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Panotopoulos J, Posch F, Alici B, Funovics
P, Stihsen C, Amann G, Brodowicz T, Windhager R and Ay C:
Hemoglobin, alkalic phoshatase, and C-reactive protein predict the
outcome in patients with liposarcoma. J Orthop Res. 33:765–770.
2015.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Sambri A, Zucchini R, Giannini C, Cevolani
L, Fiore M, Spinnato P, Bianchi G, Donati DM and De Paolis M:
Syetemic inflammation is associated with oncological outcome in
patients with high-grade myxofibrosarcoma of the extremities: A
retrospective analysis. Oncol Res Treat. 43:531–538.
2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Yanagisawa M, Gingrich AA, Judge S, Li CS,
Wang N, Thorpe SW, Kirane AR, Bold RJ, Monjazeb AM and Canter RJ:
Serum C-reactive protein and neutrophil/lymphocyte ratio after
neoadjuvant radiotherapy in soft tissue sarcoma. Anticancer Res.
38:1491–1497. 2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Sato Y, Nakano K, Wang X, Fukuda N,
Urasaki T, Ohmoto A, Hayashi N, Yunokawa M, Ono M, Tomomatsu J, et
al: Pre-treatment neutrophil-to-lymphocyte ratio (NLR) as a
predictive marker of pazopanib treatment for soft-tissue sarcoma.
Cancers (Basel). 13(6266)2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Nakamura T, Katagiri H, Shido Y, Hamada S,
Yamada K, Nagano A, Yamada S, Tsukushi S, Ishimura D, Matsumine A,
et al: Analysis of factors for predicting survival in soft-tissue
sarcoma with metastatic disease at initial presentation. Anticancer
Res. 37:3137–3141. 2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Galon J, Angell HK, Bedognetti D and
Marincola FM: The continuum of cancer immunosurveillance:
Prognostic, predictive, and mechanistic signatures. Immunity.
39:11–26. 2013.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Demaria S and Formenti SC: Radiation as an
immunological adjuvant: Current evidence on dose and fractionation.
Front Oncol. 2(153)2012.PubMed/NCBI View Article : Google Scholar
|
|
50
|
McMillan DC, Crozier JE, Canna K, Angerson
WJ and McArdle CS: Evaluation of an inflammation-based prognostic
score (GPS) in patients undergoing resection for colon and rectal
cancer. Int J Colorectal Dis. 22:881–886. 2007.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Wu TH, Tsai YT, Chen KY, Yap WK and Luan
CW: Utility of high-sensitivity modified Glasgow prognostic score
in cancer prognosis: A systematic review and meta-analysis. Int J
Mol Sci. 24(1318)2023.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Kimura S, D’ Andrea D, Soria F, Foerster
B, Abufaraj M, Vartolomei MD, Iwata T, Karakiewicz PI, Rink M, Gust
KM, et al: Prognostic value of modified Glasgow prognostic score in
non-muscle-invasive bladder cancer. Urol Oncol. 37:179.e19–179.e28.
2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Levitt DG and Levitt MD: Human serum
albumin homeostasis: a new look at the roles of synthesis,
catabolism, renal and gastrointestinal excretion, and the clinical
value of serum albumin measurements. Int J Gen Med. 9:229–255.
2016.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Gatta A, Verardo A and Bolognesi M:
Hypoalbuminemia. Intern Emerg Med. 7 (Suppl 3):S193–S199.
2012.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Spence S, Doonan J, Farhan-Alanie OM, Chan
CD, Tong D, Cho HS, Sahu MA, Traub F and Gupta S: The MPGS Study
Group. Does the modified Glasgow prognostic score aid in the
management of patients undergoing surgery for a soft-tissue
sarcoma?: An international multicentre study. Bone Joint J.
104-B:168–176. 2022.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Nakamura T, Matsumine A, Asanuma K,
Matsubara T and Sudo A: The value of the high-sensitivity modified
Glasgow prognostic score in predicting the survival of patients
with a soft-tissue sarcoma. Bone Joint J. 97-B:847–852.
2015.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Tsuda Y, Ogura K, Kobayashi E, Hiruma T,
Iwata S, Asano N, Kawai A, Chuman H, Ishii T, Morioka H, et al:
Impact of geriatric factors on surgical and prognostic outcomes in
elderly patients with soft-tissue sarcoma. Jpn J Clin Oncol.
47:422–429. 2017.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Jiang SS, Jiang L, Weng DS, Li YF, Pan QZ,
Zhao JJ, Tang Y, Zhou ZW and Xia JC: Immunization-based scores as
independent prognostic predictors in soft tissue sarcoma patients.
J Cancer. 8:606–616. 2017.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Aggerholm-Pedersen N, Maretty-Kongstad K,
Keller J and Safwat A: Serum biomarkers as prognostic factors for
metastatic sarcoma. Clin Oncol (R Coll Radiol). 31:242–249.
2019.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Hou T, Guo T, Nie R, Hong D, Zhou Z, Zhang
X and Liang Y: The prognostic role of the preoperative systemic
immune-inflammation index and high-sensitivity modified Glasgow
prognostic score in patients after radical operation for soft
tissue sarcoma. Eur J Surg Oncol. 46:1496–1502. 2020.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Mahyudin F, Edward M, Basuki MH, Basrewan
Y, Hernugrahanto KD and Wahyudiputra AG: Analysis of prognostic
factors in soft tissue sarcoma: Cancer registry from a single
tertiary hospital in Indonesia. Ann Med Surg (Lond). 57:257–263.
2020.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Nakamura T, Asanuma K, Hagi T and Sudo A:
Modified Glasgow prognostic score is better for predicting
oncological outcome in patients with soft tissue sarcoma, compared
to High-sensitivity modified Glasgow prognostic score. J Inflamm
Res. 15:3891–3899. 2022.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Nakamura T, Hagi T, Asanuma K and Sudo A:
Is lymphocyte C-reactive protein ratio useful for predicting
survival in patients with non-metastatic soft tissue sarcoma?
Cancers (Basel). 14(5214)2022.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Matsui Y, Matsuda A, Maejima A, Shinoda Y,
Nakamura E, Komiyama M and Fujimoto H: The clinical significance of
perioperative inflammatory index as a prognostic factor for
patients with retroperitoneal soft tissue sarcoma. Int J Clin
Oncol. 27:1093–1100. 2022.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Fontana R, Bregni M, Cipponi A, Raccosta
L, Rainelli C, Maggioni D, Lunghi F, Ciceri FL, Mukenge S, Doglioni
C, et al: Peripheral blood lymphocytes genetically modified to
express the self/tumor antigen mage-a3 induce antitumor immune
responses in cancer patients. Blood. 113:1651–1660. 2009.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Nishi M, Shimada M, Tokunaga T,
Higashijima J, Yoshikawa K, Kashihara H, Takasu C, Ishikawa D, Wada
Y, Eto S and Yoshimoto T: Lymphocyte to C-reactive protein ratio
predicts long-term outcomes for patients with lower rectal cancer.
World J Surg Oncol. 19(201)2021.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Yugawa K, Maeda T, Kinjo N, Kawata K,
Ikeda S, Edahiro K, Edagawa M, Omine T, Kometani T, Yamaguchi S, et
al: Prognostic impact of lymphocyte-C-reactive protein ratio in
patients who underwent surgical resection for hepatocellular
carcinoma. J Gastrointest Surg. 26:104–112. 2022.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Okugawa Y, Toiyama Y, Yamamoto A,
Shigemori T, Ichikawa T, Yin C, Suzuki A, Fujikawa H, Yasuda H,
Hiro J, et al: Lymphocyte to C-reactive protein ratio and score are
clinically feasible nutrition-inflammation markers of outcome in
patients with gastric cancer. Clin Nutr. 39:1209–1217.
2020.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Nakamura T, Matsumine A, Matsubara T,
Asanuma K, Uchida A and Sudo A: The combined use of the
neutrophil-lymphocyte ratio and C-reactive protein level as
prognostic predictors in adult patients with soft tissue sarcoma. J
Surg Oncol. 108:481–485. 2013.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Powell DR and Huttenlocher A: Neutrophils
in the tumor microenvironment. Trends Immunol. 37:41–52.
2016.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Idowu OK, Ding Q, Taktak AFG, Chandrasekar
CR and Yin Q: Clinical implication of pretreatment nuetrophil to
lymphocyte ratio in soft tissue sarcoma. Biomarkers. 17:539–544.
2012.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Cupp MA, Cariolou M, Tzoulaki I, Aune D,
Evangelou E and Berlanga-Taylor AJ: nuetrophil to lymphocyte ratio
and cancer prognosis: An umbrella review of systematic reviews and
meta-analyses of observational studies. BMC Med.
18(360)2020.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Hagi T, Nakamura T, Kita K, Iino T,
Asanuma K and Sudo A: Anti-tumour effect of tocilizumab for
osteosarcoma cell lines. Bone Joint Res. 9:821–826. 2020.PubMed/NCBI View Article : Google Scholar
|
